Flamel Technologies I

In December 2011, Deerfield made an equity investment in Flamel Technologies, a public company that owns several promising drug delivery technologies. At the time, the company’s largest holder, which had waged a successful proxy battle and influenced the selection of a significant portion of the company’s Board, was threatening to put its shares on the market.